To further explore the relationship between NAT10 expression and AR-positive prostate cancer cells, VCaP and LNCaP cells were treated with an AR agonist (DHT) or an AR antagonist (Enza) for 48 h, and protein levels of NAT10, AR, and CDC6 were analyzed by Western blotting. The gene discussed is AR; the disease is prostate carcinoma.